Preferred Label : tisagenlecleucel;
CISMeF synonym : KYMRIAH;
UNII : Q6C9WHR03O;
Origin ID : C000626284;
UMLS CUI : C3640939;
- ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- Cell [UMLS semantic type]
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3451606/fr/kymriah-tisagenlecleucel-lymphome-folliculaire
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
tisagenlecleucel
tisagenlecleucel
lymphoma, follicular
Recurrent Follicular Lymphoma
Refractory Follicular Lymphoma
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3467532/fr/kymriah-tisagenlecleucel-lymphome-diffus-a-grande-cellules-b-ldgcb
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
infusions, intravenous
tisagenlecleucel
Antineoplastic Agents, Immunological
receptors, antigen, t-cell
Anti-CD19 CAR T Cells Preparation
evaluation of the transparency committee
lymphoma, large B-Cell, diffuse
tisagenlecleucel
---
https://www.has-sante.fr/jcms/p_3396024/fr/kymriah-tisagenlecleucel-lymphome-folliculaire
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
tisagenlecleucel
adult
Refractory Follicular Lymphoma
antineoplastic agents
infusions, intravenous
evaluation of the transparency committee
tisagenlecleucel
lymphoma, follicular
---
https://www.has-sante.fr/jcms/p_3348719/fr/kymriah-tisagenlecleucel-lymphome-folliculaire
2022
France
evaluation of the transparency committee
tisagenlecleucel
malignant lymphoma, nos
lymphoma, follicular
KYMRIAH
Follicular lymphoma
tisagenlecleucel
---
https://www.has-sante.fr/jcms/p_3262259/fr/kymriah-tisagenlecleucel-ldgcb
2022
France
evaluation of the transparency committee
KYMRIAH
lymphoma, large B-Cell, diffuse
tisagenlecleucel
tisagenlecleucel
---
https://www.has-sante.fr/jcms/p_3262259/fr/kymriah-ldgcb-tisagenlecleucel
2021
false
false
false
France
Anti-CD19 CAR T Cells Preparation
treatment outcome
insurance, health, reimbursement
tisagenlecleucel
adult
lymphoma, large B-Cell, diffuse
recurrence
infusions, intravenous
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
evaluation of the transparency committee
tisagenlecleucel
receptors, antigen, t-cell
receptors, antigen, t-cell
---
https://www.has-sante.fr/jcms/p_3262256
2021
France
evaluation of the transparency committee
KYMRIAH
Cell
b lymphocyte
cells
tisagenlecleucel
burkitt lymphoma
tisagenlecleucel
b-lymphocytes
---
https://ansm.sante.fr/tableau-marr/tisagenlecleucel
2021
false
false
false
France
French
risk management
guidelines for drug use
tisagenlecleucel
infusions, intravenous
tisagenlecleucel
child
adult
patients guideline
patient education handout
tisagenlecleucel
drug storage
drug compounding
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
Adoptive Cell Therapy Agent
medical waste disposal
receptors, antigen, t-cell
receptors, antigen, t-cell
receptors, antigen, t-cell
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-le-tisagenlecleucel-pour-le-traitement-du-lymphome-diffus-a-grandes-cellules-b-recidivant-ou-refractaire.html
2019
false
false
false
Canada
tisagenlecleucel
antigens, CD19
treatment outcome
insurance, health, reimbursement
recurrence
Refractory cancer
adult
drug costs
costs and cost analysis
quality of life
tisagenlecleucel
drug evaluation
lymphoma, large B-Cell, diffuse
tisagenlecleucel
receptors, antigen, t-cell
receptors, antigen, t-cell
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-le-tisagenlecleucel-pour-le-traitement-de-la-leucemie-lymphoblastique-aigue-recidivante-ou-refractaire.html
2019
false
false
false
Canada
recurrence
acute disease
Refractory cancer
treatment outcome
insurance, health, reimbursement
tisagenlecleucel
quality of life
drug costs
costs and cost analysis
child
adolescent
survival
antigens, CD19
tisagenlecleucel
drug evaluation
tisagenlecleucel
precursor cell lymphoblastic Leukemia-Lymphoma
receptors, antigen, t-cell
receptors, antigen, t-cell
---
https://ansm.sante.fr/tableau-atu-rtu/kymriah-1-2-x-106-6-x-108-cellules-dispersion-pour-perfusion
2018
false
false
false
France
French
guidelines for drug use
summary of product characteristics
package leaflet
tisagenlecleucel
tisagenlecleucel
lymphoma, follicular
adult
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
tisagenlecleucel
risk management
infusions, intravenous
antineoplastic agents
antineoplastic agents
patients guideline
---
https://www.has-sante.fr/portail/jcms/c_2891689/fr/kymriah-lal
https://www.has-sante.fr/portail/jcms/c_2891689/fr/kymriah-tisagenlecleucel-car-t-anti-cd19-lal
2018
false
false
false
France
child
young adult
adolescent
tisagenlecleucel
tisagenlecleucel
treatment outcome
recurrence
infusions, intravenous
B Acute Lymphoblastic Leukemia
precursor b-cell lymphoblastic leukemia-lymphoma
guidelines for drug use
tisagenlecleucel
evaluation of the transparency committee
receptors, antigen, t-cell
receptors, antigen, t-cell
---
https://www.has-sante.fr/portail/jcms/c_2891692/fr/kymriah-ldgcb
https://www.has-sante.fr/portail/jcms/c_2891692/fr/kymriah-tisagenlecleucel-car-t-anti-cd19-ldgcb
2018
false
false
false
France
tisagenlecleucel
tisagenlecleucel
adult
treatment outcome
lymphoma, large B-Cell, diffuse
infusions, intravenous
recurrence
survival analysis
guidelines for drug use
tisagenlecleucel
evaluation of the transparency committee
receptors, antigen, t-cell
receptors, antigen, t-cell
---
https://www.ema.europa.eu/medicines/human/EPAR/Kymriah
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
drug approval
europe
treatment outcome
tisagenlecleucel
tisagenlecleucel
gene therapy
child
adolescent
young adult
B Acute Lymphoblastic Leukemia
precursor b-cell lymphoblastic leukemia-lymphoma
b-lymphocytes
lymphoma, large B-Cell, diffuse
adult
recurrence
infusions, intravenous
product surveillance, postmarketing
precursor b-cell lymphoblastic leukemia-lymphoma
antigens, CD19
pregnancy
breast feeding
tisagenlecleucel
drug evaluation, preclinical
genetic therapy
receptors, antigen, t-cell
receptors, antigen, t-cell
---